Role of nitric oxide scavenging in vascular response to cell-free hemoglobin transfusion

Kenji Sampei, John A. Ulatowski, Yoshio Asano, Herman Kwansa, Enrico Bucci, and Raymond C. Koehler

1Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University, Baltimore, Maryland; 2Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, Maryland

Submitted 15 March 2005; accepted in final form 6 May 2005

Modified Hb solutions have been developed as O2 carrier transfusion fluids, but of concern is the possibility that increased scavenging of nitric oxide (NO) within the plasma will alter vascular reactivity even if the Hb does not readily extravasate. The effect of decreasing hematocrit from ∼30% to 18% by an exchange transfusion of a 6% sebacoyl cross-linked tetrameric Hb solution on the diameter of pial arterioles possessing tight endothelial junctions was examined through a cranial window in anesthetized cats with and without a NO synthase (NOS) inhibitor. Superfusion of a NOS inhibitor decreased diameter, and subsequent Hb transfusion produced additional constriction that was not different from Hb transfusion alone but was different from the dilation observed by exchange transfusion of an albumin solution after NOS inhibition. In contrast, abluminal application of the cross-linked Hb produced constriction that was attenuated by the NOS inhibitor. Neither abluminal nor intraluminal cross-linked Hb interfered with pial arteriolar dilation to cromakalim, an activator of ATP-sensitive potassium channels. Pial vascular reactivity to hypocapnia and hypercapnia was unaffected by Hb transfusion. Microsphere-determined regional blood flow indicated selective dilations in the brain, with its tight endothelial junctions, providing a model with which to assess vascular reactivity in vivo without local extravasation of Hb. Previous work (1) has demonstrated that NO-dependent dilation of pial arterioles to acetylcholine and ADP was intact after exchange transfusion of cross-linked tetrameric Hb. These results suggested that plasma-based Hb did not appreciably scavenge NO evoked by agonist stimulation. However, exchange transfusion with Hb resulted in a decrease in arteriolar diameter in contrast to the dilation seen with exchange transfusion of an albumin solution. If agonist stimulation results in intermittent bursts of NO production, a sufficient amount of NO may escape scavenging by plasma-based Hb to effect arteriolar dilation (31). Thus it is possible that intraluminal Hb increases baseline vascular tone by scavenging of NO in plasma that intraluminal Hb increases baseline vascular tone by scavenging of NO in plasma that intraluminal Hb increases baseline vascular tone by scavenging of NO in plasma that intraluminal Hb increases baseline vascular tone by scavenging of NO in plasma.
enging NO without affecting vascular responsiveness to endothelial-dependent dilators.

The purpose of the present study was to determine the role of NO in the vascular response of the cerebral circulation to exchange transfusion of cell-free Hb by inhibiting NO synthase (NOS) before performing the transfusion. Measurements were made of cerebral blood flow (CBF) after systemic NOS inhibition and of pial arteriolar diameter after local NOS inhibition. Blood flow measurements in the brain were contrasted with blood flow in neurohypophysis, which does not have tight endothelial junctions, and to major peripheral vascular beds, such as kidneys, intestines, skeletal muscle, and cardiac muscle. If Hb reduces blood flow to a particular region by scavenging NO, then reducing NO availability by prior NOS inhibition should prevent Hb transfusion from decreasing blood flow. Cross-linked tetrameric Hb was used because it has been demonstrated to extravasate in renal lymph (12) and thereby to provide a positive control for effects of extravasation. Because changes in vascular resistance after exchange transfusion of cell-free Hb are influenced by changes in hematocrit and blood viscosity as well as by arteriolar tone, pial arteriolar diameter was measured after Hb transfusion with and without local NOS inhibition. In addition, the direct effect of abluminal cross-linked Hb on cerebral vascular tone was assessed by topically applying the cross-linked Hb on the pial surface with and without NOS inhibition. Specificity of NO effects on vascular tone was determined by coapplication of Hb and cromakalim, an agonist of ATP-sensitive K\(^+\) (K\(_{ATP}\)) channels, with either local application of cross-linked Hb or systemic transfusion of Hb. A K\(_{ATP}\) channel agonist was used because of its ability to produce large dilations for testing potential inhibition by Hb and because of the clinical importance of knowing whether cell-free Hb is capable of blocking responses to the activation of these channels that are known to be important in hypoxic-ischemic conditions (27, 28).

**Methods**

All procedures were approved by The Johns Hopkins University Animal Care and Use Committee and conformed to the principles of laboratory animal research outlined by the American Physiological Society and the National Institutes of Health guidelines. Cats were anesthetized with pentobarbital sodium (40 mg/kg ip). Catheters were advanced into the inferior vena cava via femoral veins for administration of fluids and drugs. Anesthesia was maintained with continuous infusion of pentobarbital sodium (6 mg·kg\(^{-1}\)·h\(^{-1}\) iv). Both femoral arteries were catheterized for measuring arterial blood pressure, sampling arterial blood, and withdrawing blood during the exchange transfusion. The lungs were mechanically ventilated to maintain arterial partial pressure of CO\(_2\) (P\(_{aCO_2}\)) at 35–40 mmHg. The arterial partial pressure of O\(_2\) (P\(_{aO_2}\)) was maintained >100 mmHg with enriched inspired O\(_2\). Rectal temperature was maintained at \(\sim 38^\circ\)C with a heating lamp and warming blanket. Arterial blood gases, total Hb concentration, and O\(_2\) saturation were made at baseline and at 50, 120, and 160 min after baseline measurements in three groups of cats (Fig. 1). In the first group (n = 12 cats), an exchange transfusion of cross-linked Hb was performed over a 40-min period starting 60 min after baseline measurements to determine the effect of the transfusion alone. In the second group (n = 9 cats), N\(^-\)nitro-L-arginine methyl ester (l-NNAME) was infused over a 5-min period starting 20 min after baseline measurements to determine the effect of NOS inhibition alone. A dose of l-NNAME (20 mg/kg iv) was chosen based on previous work (29) showing >90% inhibition of NOS activity in cats. In the third group (n = 8 cats), l-NNAME was infused at 20 min, and an exchange transfusion of Hb was performed at 60–100 min after baseline measurements to determine the effect of NOS inhibition on the subsequent response to Hb transfusion. Data within each group were analyzed by ANOVA with repeated measures (SPSS, Chicago, IL). If significant, comparisons between individual time points were performed by paired t-test with Bonferroni correction for three comparisons (between baseline and 50-min values for the effect of l-NNAME and between the 50-min values and the 120- and 160-min values for the effect of Hb transfusion). In this and all remaining experiments below, the level of significance was set at P < 0.05, and values are means ± SE.

**Pial arteriolar response to Hb transfusion after NOS inhibition.** To test whether the pial arteriolar response to exchange transfusion is influenced by prior NOS inhibition, N\(^-\)nitro-l-arginine (l-NNA) was superfused over the cortical surface through a closed cranial window before exchange transfusion of Hb. Four groups were studied (Fig. 2). In the first group (n = 9 cats), l-NNA was superfused without subsequent Hb transfusion to control for the effect of time after NOS inhibition. In the second group (n = 6 cats), l-NNA was superfused followed by an exchange transfusion with a solution of 5% human serum albumin to control for effects of reduced hematocrit. In the third group (n = 8 cats), artificial cerebrospinal fluid (CSF) was superfused followed by an exchange transfusion with the Hb solution. In the fourth group (n = 7 cats), l-NNA was superfused followed by an exchange transfusion with the Hb solution. A closed cranial
Fig. 1. Schematic diagram of experimental design involving regional blood flow measurements after administration of Ringer lactate solution or N\textsuperscript{-}nitro-L-arginine methyl ester (L-NAME) and after exchange transfusion with Hb solution in three groups of cats.

Fig. 2. Schematic diagram of experimental design involving pial arteriolar diameter measurements after superfusion of cerebrospinal fluid (CSF) or N\textsuperscript{-}nitro-L-arginine (L-NAME) and after exchange transfusion with albumin (Alb) or Hb solution in four groups of cats.
Regional blood flow with NOS inhibition and Hb transfusion. Exchange transfusion with the 6% sebagyl cross-linked Hb solution, occurring over 60–100 min after baseline measurements, reduced arterial hematocrit by one-third from ~30% to 20%. Total arterial Hb concentration was reduced by ~17% (Table 1). Reductions were similar in groups pretreated with vehicle (Ringer lactate) or L-NAME administration at 20 min after baseline measurements. No major changes were observed in arterial pH or PaCO$_2$ after administration of L-NAME, Hb transfusion, or Hb transfusion after L-NAME. In all groups, PaO$_2$ was maintained in the range of 100–150 mmHg to keep oxyhemoglobin saturation >95%.

In the group pretreated with Ringer vehicle, Hb transfusion increased MABP (Fig. 3). In the L-NAME time-control group with no Hb transfusion, MABP also increased. In the group with Hb transfusion after L-NAME pretreatment, MABP increased after L-NAME but did not increase further after Hb transfusion. Values in the latter group remained similar to those in the L-NAME control group over a 60-min period after completion of the transfusion.

Blood flow to kidneys decreased after Hb transfusion alone and after L-NAME infusion alone (Fig. 4). However, Hb transfusion after L-NAME pretreatment did not cause a further reduction in renal blood flow. The pattern was similar in the small intestine where blood flow decreased significantly 1 h after completion of the Hb transfusion. Treatment with L-NAME also decreased intestinal blood flow, and no further reduction occurred with subsequent Hb transfusion. Blood flow to skeletal muscle and the left ventricular free wall exhibited a different pattern in that the flow increased after Hb transfusion. Administration of L-NAME produced a modest decrease in blood flow to skeletal muscle but not in the left ventricle, possibly because of the offsetting effect of increased afterload and increased myocardial work. Transfusion of Hb after L-NAME treatment produced no significant change in skeletal muscle blood flow and a transient increase in coronary blood flow.

Administration of L-NAME alone decreased CBF and blood flow to the neurohypophysis (Fig. 5). Transfusion of the Hb

---

**Table 1. Physiological variables in regional blood flow experiment with no transfusion or Hb transfusion after Ringer lactate or L-NAME infusion**

<table>
<thead>
<tr>
<th>Variable</th>
<th>0</th>
<th>50</th>
<th>120</th>
<th>160</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematocrit, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ringer/Hb</td>
<td>30 ± 1</td>
<td>30 ± 1</td>
<td>20 ± 1*</td>
<td>20 ± 1*</td>
</tr>
<tr>
<td>L-NAME alone</td>
<td>28 ± 1</td>
<td>29 ± 1</td>
<td>29 ± 1</td>
<td>28 ± 1</td>
</tr>
<tr>
<td>L-NAME/Hb</td>
<td>31 ± 1</td>
<td>31 ± 1</td>
<td>20 ± 1*</td>
<td>20 ± 1*</td>
</tr>
<tr>
<td>Arterial Hb, g/dl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ringer/Hb</td>
<td>10.8 ± 0.2</td>
<td>11.1 ± 0.2</td>
<td>9.2 ± 0.2*</td>
<td>9.0 ± 0.1*</td>
</tr>
<tr>
<td>L-NAME alone</td>
<td>10.0 ± 0.2</td>
<td>10.4 ± 0.3</td>
<td>10.5 ± 0.4</td>
<td>9.8 ± 0.3</td>
</tr>
<tr>
<td>L-NAME/Hb</td>
<td>10.8 ± 0.5</td>
<td>11.6 ± 0.6</td>
<td>9.4 ± 0.3*</td>
<td>9.7 ± 0.4*</td>
</tr>
<tr>
<td>Arterial pH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ringer/Hb</td>
<td>7.42 ± 0.01</td>
<td>7.41 ± 0.01</td>
<td>7.40 ± 0.01</td>
<td>7.39 ± 0.01</td>
</tr>
<tr>
<td>L-NAME alone</td>
<td>7.42 ± 0.01</td>
<td>7.39 ± 0.01</td>
<td>7.40 ± 0.01</td>
<td>7.39 ± 0.01</td>
</tr>
<tr>
<td>L-NAME/Hb</td>
<td>7.42 ± 0.01</td>
<td>7.40 ± 0.01</td>
<td>7.38 ± 0.02</td>
<td>7.37 ± 0.01</td>
</tr>
<tr>
<td>PaCO$_2$, mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ringer/Hb</td>
<td>38 ± 1</td>
<td>39 ± 1</td>
<td>41 ± 1</td>
<td>41 ± 1</td>
</tr>
<tr>
<td>L-NAME alone</td>
<td>39 ± 1</td>
<td>40 ± 1</td>
<td>40 ± 1</td>
<td>41 ± 1</td>
</tr>
<tr>
<td>L-NAME/Hb</td>
<td>39 ± 1</td>
<td>40 ± 1</td>
<td>40 ± 2</td>
<td>41 ± 1</td>
</tr>
<tr>
<td>CMRO$_2$, ml O$_2$/min$^{-1}$</td>
<td>100 g$^{-1}$</td>
<td>3.6 ± 0.2</td>
<td>3.7 ± 0.7</td>
<td>3.4 ± 0.2</td>
</tr>
<tr>
<td>Ringer/Hb</td>
<td>3.0 ± 0.2</td>
<td>3.0 ± 1</td>
<td>2.9 ± 0.1</td>
<td>3.0 ± 0.2</td>
</tr>
<tr>
<td>L-NAME alone</td>
<td>3.2 ± 0.3</td>
<td>2.5 ± 0.2</td>
<td>2.6 ± 0.3</td>
<td>2.9 ± 0.3</td>
</tr>
</tbody>
</table>

Values are means ± SE. Times correspond to microsphere-determined blood flow with Ringer lactate or L-nitro-L-arginine methyl ester (L-NAME) infused at 20 min and Hb transfusion performed between 60 and 100 min. Ringer/Hb, Ringer lactate infusion followed by Hb transfusion ($n = 12$); L-NAME alone, L-NAME infusion followed by no transfusion ($n = 9$); L-NAME/Hb, L-NAME infusion followed by Hb transfusion ($n = 8$). PaCO$_2$, arterial partial pressure of CO$_2$; CMRO$_2$, cerebral metabolic rate of O$_2$. *$P < 0.05$ from 50-min value by repeated measures ANOVA and paired $t$-test with Bonferroni correction.

---

K$_{ATP}$ channel antagonist glibenclamide (1 $\mu$M) was superfused for 5 min. An additional 5 min was allowed to establish a new baseline diameter. Responses to 1 and 10 $\mu$M cromakalim were repeated in the presence of 1 $\mu$M glibenclamide added to the superfusate. After the window was washed out with artificial CSF, dilatatory capacity to hypercapnia was tested by adding 5% CO$_2$ to the inspired gas mixture. For each size vessel, percent changes in diameter were analyzed by two-way ANOVA with repeated measures, where Hb transfusion was a within-subject factor. For each dose of cromakalim, comparisons before and after glibenclamide were made by paired $t$-test.

Pial arteriolar responses to K$_{ATP}$ channel agonist after Hb superfusion. To test whether abluminal application of cross-linked Hb tetramer interfered with dilation to a K$_{ATP}$ channel activator, the dilator response to 1 and 10 $\mu$M cromakalim was tested in the presence of 0.1, 1, and 10 $\mu$M cross-linked Hb. After we obtained a control response to superfusion of the cranial window with either 1 $\mu$M cromakalim ($n = 3$ cats) or 10 $\mu$M cross-linked Hb, the window was superfused with 0.1 $\mu$M cross-linked Hb for 5 min, and then 1 and 10 $\mu$M Hb superfusion. The percent change in diameter in response to cromakalim at each Hb concentration was analyzed by repeated measures ANOVA.

---

**RESULTS**

Regional blood flow with NOS inhibition and Hb transfusion. Exchange transfusion with the 6% sebagyl cross-linked Hb solution, occurring over 60–100 min after baseline measurements, reduced arterial hematocrit by one-third from ~30% to 20%. Total arterial Hb concentration was reduced by ~17% (Table 1). Reductions were similar in groups pretreated with vehicle (Ringer lactate) or L-NAME administration at 20 min after baseline measurements. No major changes were observed in arterial pH or PaCO$_2$ after administration of L-NAME, Hb transfusion, or Hb transfusion after L-NAME. In all groups, PaO$_2$ was maintained in the range of 100–150 mmHg to keep oxyhemoglobin saturation >95%.

In the group pretreated with Ringer vehicle, Hb transfusion increased MABP (Fig. 3). In the L-NAME time-control group with no Hb transfusion, MABP also increased. In the group with Hb transfusion after L-NAME pretreatment, MABP increased after L-NAME but did not increase further after Hb transfusion. Values in the latter group remained similar to those in the L-NAME control group over a 60-min period after completion of the transfusion.

Blood flow to kidneys decreased after Hb transfusion alone and after L-NAME infusion alone (Fig. 4). However, Hb transfusion after L-NAME pretreatment did not cause a further reduction in renal blood flow. The pattern was similar in the small intestine where blood flow decreased significantly 1 h after completion of the Hb transfusion. Transfusion with L-NAME also decreased intestinal blood flow, and no further reduction occurred with subsequent Hb transfusion. Blood flow to skeletal muscle and the left ventricular free wall exhibited a different pattern in that the flow increased after Hb transfusion. Administration of L-NAME produced a modest decrease in blood flow to skeletal muscle but not in the left ventricle, possibly because of the offsetting effect of increased afterload and increased myocardial work. Transfusion of Hb after L-NAME treatment produced no significant change in skeletal muscle blood flow and a transient increase in coronary blood flow.

Administration of L-NAME alone decreased CBF and blood flow to the neurohypophysis (Fig. 5). Transfusion of the Hb

---

**Fig. 3. Mean arterial blood pressure (means ± SE) in a group ($n = 12$ cats) exchange transfused with cross-linked Hb between 60 and 100 min (left), in a group ($n = 9$ cats) infused with L-NAME at 20 min (middle), and in a group ($n = 8$ cats) infused with L-NAME at 20 min and exchange transfused with cross-linked Hb between 60 and 100 min (right). *$P < 0.05$ between 0- and 50-min values; +$P < 0.05$ from 50-min value (repeated measures ANOVA and paired $t$-test with Bonferroni correction).**
solution alone produced no change in CBF but did produce a large decrease in blood flow to the neurohypophysis, which does not have a blood-brain barrier. After pretreatment with L-NAME, no additional decrease in neurohypophyseal blood flow occurred with Hb transfusion. CBF transiently increased by 20% at 20 min after the Hb transfusion but returned to the post-L-NAME value at 60 min after the transfusion. Repeated measures ANOVA did not indicate a significant change in cerebral O2 consumption in any group over time (Table 1).

Vascular resistances were analyzed for each organ, and percent changes were calculated to plot regional changes on the same scale in Fig. 6. Transfusion of Hb alone increased vascular resistance in the kidney and intestine, decreased resistance in the skeletal muscle and left ventricle, and produced no change in CVR. Infusion of L-NAME increased vascular resistance in all organs, with the kidney and intestine being most prominent on a percentage basis. Transfusion of Hb after L-NAME infusion did not produce an increase in resistance in any organ; resistance in the left ventricle and cerebrum decreased significantly.

**Pial arteriolar response to Hb transfusion after NOS inhibition.** Superfusion of L-NNA through the cranial window produced constriction of pial arterioles of all sizes, whereas no changes in diameter occurred in the group superfused with CSF (Fig. 7A). The degree of constriction with L-NNA was similar in the time-control group and in the groups to be transfused subsequently with albumin and Hb. The initial constriction partially subsided over time, resulting in a modest dilation in the time-control group compared with the initial diameter after L-NNA superfusion (Fig. 7B). Exchange transfusion with the albumin solution after L-NNA superfusion produced dilation. Exchange transfusion with the Hb solution after CSF superfusion produced constriction. After L-NNA superfusion, Hb transfusion initially produced 12 ± 2%, 12 ± 2%, and 9 ± 1% constriction in small, medium, and large vessels, respectively, in addition to the constriction that occurred with L-NNA. In some cats, this additional constriction, measured at the completion of the exchange transfusion, subsided somewhat 30 min later. However, the response measured 30 min after the transfusion (Fig. 7B) was not significantly different from the time-matched response in the Hb-transfused group with CSF superfusion but was significantly less than the change in diameter observed in the L-NNA time-control group and the group transfused with albumin after L-NNA. The increase in MABP after transfusion was similar in the Hb groups superfused with CSF and L-NNA (Table 2). A slight increase in PaCO2 occurred in the Hb-transfused group after CSF superfusion. As expected, the decrease in arterial Hb concentration was greater in the albumin-transfused group than in the Hb-transfused groups at equivalent reductions in hematocrit (Table 2).

To demonstrate whether pial arterioles were still capable of constriction after treatment with L-NNA and Hb transfusion, reactivity to hypocapnia was tested and compared with the percent constriction before L-NNA and Hb transfusion. Constriction occurred in all groups after either L-NNA, Hb transfusion, or the combination of both. The percent constriction was attenuated after L-NNA alone in large size vessels and after L-NNA plus albumin transfusion in small size arterioles compared with the baseline hypocapnic response by paired t-test (Fig. 8). No significant changes occurred in other sized vessels in these groups or in any sized vessel in the two groups receiving Hb.
Pial arteriolar response to Hb superfusion after NOS inhibition. Abluminal application of sebacyl cross-linked Hb was previously found to constrict pial arterioles (1). To determine whether NOS inhibition could reduce the direct effects of abluminal cross-linked Hb on pial arterioles, the window was superfused with cross-linked Hb before and after exposure to L-NNA in the CSF. Before superfusion of L-NNA, placement of 1 and 10 mM cross-linked Hb in the window CSF decreased the diameter of arterioles of all sizes (Fig. 9). Two-way repeated measures ANOVA indicated an overall effect of L-NNA on the response to the two Hb concentrations. Individual comparisons with paired t-test at each dose indicated that L-NNA significantly reduced the constrictor response to cross-linked Hb superfusion in all vessel sizes.

Pial arteriolar responses to KATP channel agonist after Hb transfusion. Opening of KATP channels is important in cerebrovascular dilation to various stimuli, including decreased
oxygenation (27, 28). The ability of pial arterioles to dilate to the K$_{\text{ATP}}$ channel activator cromakalim was tested after transfusion of Hb. As in previous groups, exchange transfusion produced a decrease in hematocrit (30 ± 1% to 18 ± 1%), a decrease in total Hb concentration (9.8 ± 0.2 to 7.8 ± 0.1 g/dl), and an increase in MABP (123 ± 4 to 143 ± 2 mmHg). Plasma Hb concentration was 2.2 ± 0.2 g/dl. PaCO$_2$ after Hb transfusion (41 ± 1 mmHg) was similar to that in a time-

control group with no transfusion (40 ± 1 mmHg). Superfusion of the 0.03% dimethyl sulfoxide vehicle alone had no significant effect on baseline arteriolar diameter in any size vessel (small, −0.2 ± 1.0%; medium, −0.5 ± 1.3%; large, 3.1 ± 1.3%). Responses to cromakalim were calculated as a percentage of the baseline diameter after exposure to vehicle. Superfusion of 1 and 10 μM cromakalim produced dose-dependent dilation in all sized pial arterioles (Fig. 10). The responses were similar in control and Hb-transfused groups. Application of the K$_{\text{ATP}}$ channel antagonist glibenclamide (1 μM) blocked the dilator response to 1 μM cromakalim and attenuated the response to 10 μM cromakalim to the same extent in both groups. After washout of glibenclamide, reactivity to hypercapnia was tested by increasing PaCO$_2$ from 40 ± 1 to 58 ± 2 mmHg in the control group and from 41 ± 1 to 59 ± 2 mmHg in the Hb-transfused group. For each vessel

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pretransfusion</th>
<th>Posttransfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>MABP, mmHg</td>
<td>100 ± 3</td>
<td>98 ± 5</td>
</tr>
<tr>
<td>L-NNA/Control</td>
<td>96 ± 3</td>
<td>95 ± 4</td>
</tr>
<tr>
<td>L-NNA/Alb</td>
<td>111 ± 6</td>
<td>129 ± 9*</td>
</tr>
<tr>
<td>L-NNA/Hb</td>
<td>104 ± 7</td>
<td>119 ± 6*</td>
</tr>
<tr>
<td>PaCO$_2$, mmHg</td>
<td>39 ± 1</td>
<td>40 ± 1</td>
</tr>
<tr>
<td>Arterial Hb, g/dl</td>
<td>8.9 ± 0.4</td>
<td>9.1 ± 0.4</td>
</tr>
<tr>
<td>L-NNA/Control</td>
<td>9.4 ± 0.5</td>
<td>6.1 ± 0.1*</td>
</tr>
<tr>
<td>L-NNA/Alb</td>
<td>9.4 ± 0.3</td>
<td>7.8 ± 0.1*</td>
</tr>
<tr>
<td>L-NNA/Hb</td>
<td>8.3 ± 0.1</td>
<td>7.5 ± 0.1*</td>
</tr>
</tbody>
</table>

Values are means ± SE. Pretransfusion after cerebrospinal fluid (CSF) or N$^\ominus$-nitro-l-arginine (L-NNA) superfusion and 30-min posttransfusion. L-NNA/Control, L-NNA time-control group (no transfusion; n = 9); L-NNA/Alb, group transfused with albumin after L-NNA (n = 6); CSF/Hb, group transfused with Hb after CSF superfusion (n = 8); and L-NNA/Hb, group transfused with Hb after L-NNA superfusion (n = 7). MABP, mean arterial blood pressure. *P < 0.05 from pretransfusion by paired t-test.

Fig. 8. Percent change in pial arteriolar diameter (means ± SE) during hypocapnia at the beginning of the protocol before L-NNA superfusion or exchange transfusion (pre-) and after intervention (post-) with either superfusion of L-NNA and no transfusion (L-NNA/Control; n = 9 cats), with superfusion of L-NNA and subsequent exchange transfusion of Alb solution (L-NNA/Alb; n = 6 cats), with superfusion of artificial CSF and subsequent exchange transfusion of cross-linked Hb solution (CSF/Hb; n = 8 cats), and with superfusion of L-NNA and subsequent exchange transfusion of cross-linked Hb solution (L-NNA/Hb; n = 7 cats). Responses were segregated by vessels with initial diameters of <50 μm, 50–100 μm, and >100 μm. *P < 0.05 from corresponding pretransfusion response by paired t-test.

Fig. 9. Percent change in pial arteriolar diameter (means ± SE) after 5-min superfusion of cranial window with Hb-transfused groups. Responses were segregated by vessels with initial diameters of <50 μm, 50–100 μm, and >100 μm. *P < 0.05 from corresponding value before L-NNA by repeated measures ANOVA and paired t-test.
size, the percent increase in diameter during hypercapnia was similar in the control and Hb-transfused groups (Fig. 11).

Pial arteriolar responses to $K_{\text{ATP}}$ channel agonist after Hb superfusion. The effect of increasing the CSF concentration of cross-linked Hb on the pial arteriolar response to cromakalim was investigated by superfusing the window stepwise with 0, 0.1, 1, and 10 $\mu$M cross-linked Hb and either 1 or 10 $\mu$M cromakalim. Dilation to either dose of cromakalim was not significantly affected by any dose of Hb in arterioles of any size (Fig. 12).

DISCUSSION

The major findings of this study are as follows: 1) exchange transfusion of cell-free tetrameric cross-linked Hb produced selective decreases in regional blood flow to tissues without tight endothelial junctions, such as the kidney, small intestine, and neurohypophysis; 2) these regional reductions in blood flow after Hb transfusion were blocked by treatment with a NOS inhibitor; 3) in the cerebrum where Hb exchange transfusion produced no change in blood flow and a decrease in pial arteriolar diameter, the pial arteriolar constrictor response to Hb transfusion was unaffected by local application of a NOS inhibitor; 4) abluminal application of the cross-linked Hb to pial arterioles in vivo can directly produce constriction that is NOS dependent; 5) plasma-based Hb does not exert a major effect on pial arteriolar reactivity to hypocapnia, hypercapnia, or $K_{\text{ATP}}$ channel activation; and 6) abluminal Hb application does not interfere with pial arteriolar dilation to $K_{\text{ATP}}$ channel activation.

Because adverse effects reported in clinical trials of a tetrameric cross-linked Hb solution in patients with hemorrhagic shock and stroke were thought to be attributed to NO scavenging and a resultant peripheral vasoconstriction, efforts have been directed at designing Hb molecules with decreased NO affinity (14, 18). Our data showing that increases in MAPB after tetrameric Hb transfusion were blocked by prior L-NAME treatment support the concept that hypertension induced by transfusion of cell-free Hb tetramers is attributed to scavenging of NO. However, the percent increase in vascular resistance was heterogeneous among organs. The hypertensive response was primarily the result of increased vascular resistance in the kidney and small intestines. Vascular resistance was unchanged in the cerebrum and decreased in the skeletal and cardiac muscle. Cerebral, coronary, and skeletal muscle vascular beds have smaller capillary pores than kidney and intestines (17) and are less likely to permit extravasation of the 64-kDa cross-linked tetramer. Although cross-linked tetrameric Hb does not appear in urine, it does appear in renal lymph draining the peritubular capillary bed (12). In contrast, any extravasation into CSF is too small to functionally impair NO-dependent dilation to acetylcholine and ADP (1). The increase in vascular resistance in the kidney and intestines after Hb transfusion was blocked by prior NOS inhibition, thereby indicating that the increase in resistance required basal amounts of NO. It should be noted that this conclusion assumes that any vasoconstrictive property of cross-linked Hb not mediated by NO scavenging could still have exerted an additional vasoconstrictive effect when blood flow was already markedly reduced by L-NAME. Previous work (35) with a reverse protocol sequence in which L-NAME was infused after transfusion of a fumaryl cross-linked Hb failed to show a further reduction in renal and intestinal blood flow with NOS inhibition. The lack of an increase in vascular resistance in the skeletal and cardiac muscle and the cerebrum after Hb transfusion in the present study did not appear to be due to a lack of tonic NO production because NOS inhibition alone increased vascular resistance in these beds and decreased blood flow in skeletal muscle and cerebrum. (The lack of a significant decrease in coronary blood flow with L-NAME alone may have been due to the increase in afterload and consequent increase in $O_2$ consumption.) Although part of the increase in vascular resistance after L-NAME administration may be the result of an autoregulatory response to the increase in MAPB, the increase in MAPB was equivalent to that occurring after Hb transfusion when vascular resistance failed to increase in these beds. Taken together, these data support the concept that an increase in vascular resistance after tetrameric cross-linked Hb transfusion is primarily attributed to scavenging of NO by extravasated Hb.
in selected vascular beds rather than by Hb in the plasma space. Thus these results suggest that increasing the size of the Hb molecule would be more effective in limiting vasoconstriction than would engineering modest decreases in NO affinity. The lack of a major hypertensive response with transfusion of Hb molecules polymerized by glutaraldehyde (7), together with our own data (12) of a zero-link Hb polymer that does not appear in renal lymph and does not increase MABP, supports the concept of limiting extravasation in the design of these oxygen carriers.

Blood flow results in the neurohypophysis, in which the blood vessels are highly permeable and NO exerts a tonic vasodilatory effect (37), offer a useful contrast with the rest of the brain. Whereas L-NNAME decreased blood flow in both the cerebrum and neurohypophysis, Hb transfusion decreased blood flow only in neurohypophysis. Moreover, prior treatment with L-NNAME prevented further reductions in neurohypophyseal blood flow by Hb transfusion. This finding agrees with previous work (33) showing that L-NNAME administration after Hb transfusion did not produce further reductions in neurohypophyseal blood flow. Therefore, results in the neurohypophysis also lend support to an abluminal site as the primary functional location of NO scavenging by tetrameric Hb.

Direct measurements of diameter of pial arteriolar resistance vessels on the brain surface revealed that abluminal application of the sebacyl cross-linked Hb produced constriction that was inhibited by L-NNA. Thus the chemical cross-linking of the Hb molecule did not block the ability of the tetramer to constrict arterioles by a NO-dependent mechanism. However, when the cross-linked Hb was transfused, the initial constrictor response in pial arterioles was not blocked by L-NNA, and the response remained significantly different from the responses observed in control groups with no transfusion or with albumin transfusion at equivalent hematocrit. The concentration of Hb in the plasma after the exchange transfusion was ~300 μM, which greatly exceeded the abluminal concentration of 10 μM used to generate similar constriction of pial arterioles. Therefore intraluminal NO scavenging is not the primary mechanism of the pial arteriolar constriction seen after an exchange transfusion of cross-linked Hb. The constriction is not related to a decrease in energy metabolism because Hb transfusion did not decrease cerebral O2 consumption. The constriction is more likely attributed to 1) an autoregulatory response to the increase in MABP or 2) the decrease in blood viscosity associated with the decrease in hematocrit. Blood viscosity is decreased ~25% after cross-linked Hb exchange transfusion to a hematocrit of 18% in the cat (33). Studies (16) with exchange transfusion of the large zero-link polymer of bovine Hb to the same hematocrit demonstrated that pial arterioles still constricted after the transfusion in the absence of an increase in MABP but that the constriction can be reversed to dilation when plasma viscosity is concurrently increased. Thus the constrictor response to cell-free Hb transfusion does not require arterial hypertension. Rather, the constriction of pial arterioles apparently offsets the decrease in blood viscosity associated with decreased hematocrit and results in no change in CBF when O2-carrying capacity is preserved by cell-free Hb.

Increased unloading of O2 by plasma-based Hb is also considered to contribute to vasoconstriction after Hb transfusion (19), particularly when the O2 affinity is low (30). The currently used cross-linked Hb with a P50 of 34 mmHg would be expected to enhance precapillary O2 loss and enhance constriction. Although the lack of further increases in vascular resistance when Hb was transfused after NOS inhibition argues against the importance of this mechanism, we cannot exclude that the increase in vascular resistance resulting from NOS inhibition may have mitigated the ability of increased oxygenation to produce further increases in vascular resistance. In addition, the pial arteriolar diameter measurements indicate that resistance vessels can, in fact, constrict in response to Hb transfusion after NOS inhibition but that the concurrent decrease in viscosity offsets an increase in vascular resistance.

Cell-free Hb can scavenge NO more effectively than red blood cell-based Hb (11, 36), and mathematical models of NO transport in arterioles predict that NO concentration in arteriolar smooth muscle will be markedly reduced by the presence of Hb in the plasma (8, 9). If Hb does scavenge NO in the plasma space, the present results indicate that the amount scavenged is inadequate to account for changes in basal diameter after Hb transfusion, and previous work (1) indicates that the amount scavenged is inadequate to impair NO-dependent dilation to the agonist stimulation.

Inhibition of neuronal NOS attenuates cerebrovascular dilation during hypercapnia (6). However, cross-linked Hb transfusion did not attenuate hypercapnic dilation of pial arterioles of any size, in agreement with previous work (16) in which polymerized Hb was transfused. The constrictor response to hypocapnia was also intact after cross-linked Hb transfusion. These results indirectly suggest that plasma-based Hb does not scavenge neuronal derived NO in large quantities.

One potential limitation of studying pial arterioles is that intraparenchymal arterioles may behave differently. Because of their large surface area, capillary endothelia represent a significant source of NO that could be scavenged by plasma-based Hb and could influence the concentration of NO in intraparenchymal arteriolar smooth muscle (9, 32). Measurements of CBF, which depends on both intraparenchymal and extraparenchymal resistance, showed a transient increase from a reduced baseline value when Hb was transfused after NOS inhibition, whereas CBF was not significantly changed by Hb transfusion in the absence of NOS inhibition. Perhaps the scavenging of NO in capillary endothelium by Hb limited the increase in CBF that might be anticipated at reduced blood viscosity and selectively enhanced intraparenchymal arteriolar tone.

The present work demonstrates that pial arteriolar dilation to cromakalim was not impaired by the presence of Hb in either the plasma space or in the CSF. Basilar artery dilation to a KATP channel activator has been reported to remain intact 2 days after cisternal injection of blood (26). Because the release of Hb from red blood cells after subarachnoid hemorrhage plays a role in vasospasm, our results with an acute application of Hb in the CSF also support the potential of KATP channel activators as a therapeutic target for subarachnoid hemorrhage. Pharmacological evidence indicates that KATP channels play an important role in cerebrovascular regulation in a variety of conditions, such as hypoxia (27, 28). Previous work (34) with sebacyl cross-linked Hb transfusion demonstrated that the increase in CBF during graded hypoxic hypoxia was equivalent to that in controls when one adjusted for differences in arterial O2 content. With the assumption that the vasodilatory response to hypoxia remained dependent on the activation of KATP.
channels after Hb transfusion, these results are consistent with the present finding of intact pial arteriolar dilation to cro-
makalim after Hb transfusion. It has also been proposed that the
release of NO bound to cysteine residues on red blood cell-
based Hb during deoxygenation may contribute to hypoxic
vasodilation (13, 24). However, free NO released from red
blood cells would be readily scavenged by Hb in the plasma.
Thus the normal CBF response to hypoxia previously observed
in the presence of cell-free Hb implies that the release of free
NO into the plasma by red blood cells is not essential for
hypoxic vasodilation in the brain. An alternative mechanism
involving NO storage in a nitrite pool, which can be converted
to NO in the presence of deoxyhemoglobin (4), might still be
operative in the presence of plasma-based deoxyhemoglobin,
which could release NO at the plasma-endothelial wall inter-
face.

In summary, our results with exchange transfusion of a
cross-linked tetrameric Hb indicate that peripheral vasocon-
striction that was blocked by prior NOS inhibition is most
likely attributed to scavenging of NO by extravasated Hb
because the effect was most prominent in vascular beds with
more porous endothelium. In contrast, in pial arterioles with
tight endothelial junctions, the constriction that occurred after
exchange transfusion of the Hb solution was not blocked by
NOS inhibition. This constrictor response apparently offsets
the decrease in blood viscosity to keep CBF constant and to
possibly limit overoxygenation of the brain. Furthermore, cell-
free Hb transfusion did not interfere with pial arteriolar re-
ponses to hypercapnia, hypocapnia, or KATP channel activa-
tion. These findings, together with previous data showing intact
dilatory responses to hypoxia (34) and to abluminal application
of acetylcholine, ADP and NO donors (1), indicate that the
presence of cross-linked Hb in the plasma does not adversely
affect vascular reactivity to diverse stimuli in a vascular bed
with tight endothelial junctions. These results imply that the
design of large Hb molecules that do not extravasate should help
preserve arteriolar reactivity in other vascular beds with more porous endothelium.

ACKNOWLEDGMENTS

The authors thank Tzipora Sofare for editorial assistance.

GRANTS

This work was supported by National Institutes of Health Grants NS-38684 and HL-48517.

REFERENCES

1. Asano Y, Koehler RC, Ulatowski JA, Traystman RJ, and Bucci E. Effect of crosslinked hemoglobin transfusion on endothelial dependent

2. Bucci E, Razynska A, Kwansa H, Gryczynski Z, Collins JJ, Front-
ticelli C, Unger R, Braxenthaler M, Moult J, Ji X, and Gilliland G. Positive and negative cooperativities at subsequent steps of oxygenation
regulate the allosteric behavior of multistate sebacylhemoglobin. Bio-

Ulatowski JA, and Koehler RC. Production and characteristics of an
infusible oxygen-carrying fluid based on hemoglobin intramolecularly

Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H,
Kim-Shapiro DB, Schechter AN, Cannon RO III, and Gladwin MT.

5. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, and Lemon DD. Rate of reaction with nitric oxide determines the hypertensive

6. Idecoca C and Zhang F. Permissive and obligatory roles of NO in

7. Johnson JL, Moore EE, Offner PJ, Haenel JB, Hides GA, and Tamura DY. Resuscitation of the injured patient with pstroma-free hemoglobin does not produce systemic or pulmonary hyper-


in an arteriole: impact of hemoglobin-based blood substitutes. Am J

Detailed description of a cranial window technique for acute and chronic

takeup by erythrocytes is primarily limited by extracellular diffusion

response to infusions of a nonextravasating hemoglobin polymer. J Appl

13. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE,
Stolp BW, Gow AJ, Pawloski JR, Watke P, Singel DJ, Piantadosi CA,
and Stamler JS. Nitric oxide in the human respiratory cycle. Nat Med

14. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, and Lemon DD.
NO scavenging and the hypertensive effect of hemoglobin-based blood

15. Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ,
and Colburn WA. Phase I study of the safety and pharmacologic effects

16. Reibel A, Ulatowski JA, Kwansa H, Bucci E, and Koehler RC. Cere-
brovascular response to decreased hematocrit: effect of cell-free hemoglo-
bin, plasma viscosity, and CO2. Am J Physiol Heart Circ Physiol 285:

of saline infusion on blood-tissue albumin transport. Am J Physiol Heart

18. Resta TC, Walker BR, Eichinger MR, and Doyle MP. Rate of NO
scavenging alters effects of recombinant hemoglobin solutions on pulmo-

19. Rohlfis RJ, Bruner E, Chiu A, Gonzales A, Gonzales ML, Magde D,
Magde MD Jr, Vandegriff KD, and Winslow RM. Arterial blood pressure
responses to cell-free hemoglobin solutions and the reaction with nitric

20. Sakai H, Hara H, Yuasa M, Tsai AG, Takeoka S, Tsuchida E, and
Intaglietta M. Molecular dimensions of Hb-based O2 carriers determine
constriction of resistance arteries and hypertension. Am J Physiol Heart

RJ, Stern KN, and Koudstaal PJ. Controlled safety study of a hemo-
globin-based oxygen carrier, DLCBh, in acute ischemic stroke. Stroke 30:

22. Saxena R, Wijnhoud AD, Man in’t Veld AJ, van den Meiracker AH,
Boomsma F, Przybelski RJ, and Koudstaal PJ. Effect of diaspirin
cross-linked hemoglobin on endothelin-1 and blood pressure in acute

23. Sharma A, Singh G, and Gulati A. Role of NO mechanism in cardio-
vascular effects of diaspirin cross-linked hemoglobin in anesthetized rats.

24. Singel DJ and Stamler JS. Chemical physiology of blood flow regulation

HbXL99: a hemoglobin derivative that is cross-linked between the α
subunits is useful as a blood substitute. Proc Natl Acad Sci USA 84:


